Orion Corporation (Finnish: Orion Oyj),[2][3] founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.[4]
 | |
Native name | Orion Oyj |
|---|---|
| Company type | Julkinen osakeyhtiö |
| Nasdaq Helsinki: ORNAV,ORNBV | |
| Industry | Pharmaceutical industry |
| Founded | 21 September 1917 |
| Headquarters | Espoo, Finland |
Key people | Liisa Hurme (President and CEO), Mikael Silvennoinen (Chairman) |
| Products | Pharmaceuticals and active pharmaceutical ingredients |
| Revenue |  €1.041 billion (2021) |
| €243.3 million (2021) | |
| €193.8 million (2021) | |
| Total assets | €1.114 billion (2021) |
| Total equity |  €747.9 million (2021) |
Number of employees | 3,364 (2021) |
| Website | www |
| Footnotes / references [1] | |
Orion's class A and B shares are listed on the Helsinki Stock Exchange.
History edit
Orion was founded on September 21, 1917 by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Before founding Orion, they worked in a pharmaceutical-chemical factory called Medica. The first premises of the new company were found in a courtyard building in Helsinki's Kruununhaka, Mariankatu 24, i.e. Asunto Oy Mars star. Among the first products of the apothecary were Bellistol gun oil and dulcine.[5] Pediatrician Arvo Ylppö played a significant role starting in the 1920s.[6]
Orion's diagnostics business was previously concentrated in the Orion Diagnostica profit unit, which was sold to a private equity investor in April 2018.[7] The diagnostics business included the development, manufacture and marketing of diagnostic tests and hygiene tests. Orion Diagnostica changed its name in November 2019 and is now Aidian.[8]
Notable products edit
The following are Orion's top-selling product lines as of March 2021.[9]
| Trade name | Indication |
|---|---|
| Stalevo, Comtess, Comtan | Parkinson's disease |
| Easyhaler | asthma, COPD |
| Simdax | acute heart failure |
| dexdor | intensive care sedative |
| Dexdomitor, Domitor, Domosedan, Antisedan | animal sedatives |
| Nubeqa | non-metastatic castration-resistant prostate cancer |
| Solomet | inflammation |
| Divina series | menopausal symptoms |
| Burana | inflammatory pain |
| Marevan | anticoagulant |
References edit
- ^ https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_fy_2021.pdf [bare URL PDF]
- ^ "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
- ^ "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
- ^ "About Orion".
- ^ "Orionin virstanpylväitä 1910-luvulla". www.orion.fi. Retrieved 25 July 2022.
- ^ "Orionin vahva mies | Arvo Ylppö". www.ylppo.fi. Retrieved 25 July 2022.
- ^ Moran, Mark (18 May 2018). "AJP Board Member Responds to NYT Story On Antidepressant Withdrawal". Psychiatric News. 53 (10). doi:10.1176/appi.pn.2018.5b14. ISSN 0033-2704.
- ^ "Orion Diagnostica on nyt Aidian". Aidian (in Finnish). Retrieved 25 July 2022.
- ^ https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_q1_2021_slides.pdf [bare URL PDF]